Liberty Media announces Stefano Domenicali to be appointed President and CEO of Formula 1 Sept. 25, 2020 13:05 UTC Liberty Media announces Stefano Domenicali to be appointed President and CEO of Formula 1 Chase Carey to become non-executive Chairman ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Liberty Media Corporation (“Liberty Media”) (NASDAQ: LSXMA, LSXMB, LSXMK, BATRA, BATRK, FWONA, FWONK) announced today that Stefano Domenicali will assume the role of President and CEO of Formula 1 in January 2021. Chase Carey, the current Chairman and CEO, will move to the role of non-executive Chairman. “Chase has done a phenomenal job leading F1. He assembled a first-class commercial and s

U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update Sept. 25, 2020 10:15 UTC U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update LAUSANNE, Switzerland--(BUSINESS WIRE)-- Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes. The latest edition features an overview of the historic decision made by the U.S. Food and Drug Administration (FDA) to authorize the marketing of the IQOS Tobacco Heating System with reduced exposure information. The Scient

APi Group Corporation Announces DTC Eligibility for its Warrants Sept. 25, 2020 11:03 UTC APi Group Corporation Announces DTC Eligibility for its Warrants NEW BRIGHTON, Minn.--(BUSINESS WIRE)-- APi Group Corporation (the “Company”) (NYSE: APG) announces today that (i) its warrants to purchase common stock of the Company (“Warrants”) are now eligible for repositioning into the Depository Trust & Clearing Corporation (“DTC”) and (ii) repositioned Warrants are now eligible for transfer or exercise through DTC (“DTC Eligibility”). In connection with the Company’s previously announced change of jurisdiction of incorporation from the British Virgin Islands to Delawar

ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children Sept. 25, 2020 12:30 UTC ULTOMIRIS® (ravulizumab) Receives Approval in Japan for Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Children – ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, reducing the treatment burden for adults and children with administration every other month – – ULTOMIRIS has the potential to become the new standard of care in Japan for the treatment of aHUS, an ultra-rare disease which may progressively damage the kidney and other organs – BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDA

Cannae Holdings and Senator Investment Group Send Letter to CoreLogic Shareholders Sept. 25, 2020 12:00 UTC Cannae Holdings and Senator Investment Group Send Letter to CoreLogic Shareholders Cannae and Senator’s Offer to Acquire CoreLogic at $66.00/Share Represents 39% Premium to Unaffected Share Price – Open to Raising Bid if Granted Diligence Current Board Has Overseen Substantial Value Destruction, With Company Underperforming Peers by 145% Over the Past Five Years CoreLogic Has Never Organically Grown Revenue – Yet Misleadingly Attempts to Use Acquisitions to Claim Growth Given Current Board’s Unwillingness to Engage, Nine New, Truly Independent Directors Are Neede

Colony Capital Announces Final Results of Tender Offer for Outstanding 3.875% Convertible Senior Notes Due 2021 Sept. 25, 2020 12:50 UTC Colony Capital Announces Final Results of Tender Offer for Outstanding 3.875% Convertible Senior Notes Due 2021 LOS ANGELES--(BUSINESS WIRE)-- Colony Capital, Inc. (the “Company”) today announced the expiration and final results of the Company’s previously announced cash tender offer (the “Offer”) for any and all of its outstanding 3.875% Convertible Senior Notes due 2021 (the “Convertible Notes”). The Offer expired at 12:00 midnight, New York City time, at the end of September 24, 2020. As of the expiration of the Offer, $81,309,